Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR

Phase 2 Completed 10 enrolled Columbia University Attralus, Inc. · collab

Non-randomizedParallel-groupOpen-labelDiagnostic

Summary

This was a single center, prospective cohort study that is evaluating the ability of 124I-evuzamitide PET scanning to detect potential therapeutic changes in subjects under treatment for ATTR after one year had elapsed since their original 124I-evuzamitide PET scan. Ten previously scanned subjects re-consented to undergo another 124I-evuzamitide PET scan. Demographic, clinical and phenotypic data were collected to characterize potential changes since their previous scans.

Timeline

Start: 2022-07-08
Primary completion: 2024-05-07
Completion: 2024-06-12

Publications

Smiley DA, Einstein AJ, O'Gorman KJ, Santana D, Teruya S, Chan N, Nalbandian A, Poterucha TJ, Helmke ST, Mintz A, Goldner K, Sekulic M, Mirabal A, Cuomo MO, Guadalupe S, De Los Santos J, Paulino ME, Mateo KA, Rodriguez CM, Jimenez M, Wardhere A, Bampatsias D, Castillo M, Peng B, Maurer MS. Early Detection of Transthyretin Cardiac Amyloidosis Using 124I-Evuzamitide Positron Emission Tomography/Computed Tomography. JACC Cardiovasc Imaging. 2025 Jul;18(7):799-811. doi: 10.1016/j.jcmg.2025.01.018. Epub 2025 May 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Evuzamitide	Peptide	—	—

Indications

No indication recorded.